Increased UTI risk not seen in ‘real world’ use of SGLT-2 inhibitors

Concerns about risk of serious urinary tract infections with SGLT2 inhibitors have not been reflected in real world use, the authors of a US study say. The risk for severe and non-severe UTI events in patients starting SGLT-2 inhibitor therapy was similar to that among patients starting treatment with other antidiabetic medications such as DPP-4 ...

Already a member?

Login to keep reading.

© 2021 the limbic